Quassinoids: From Traditional Drugs to New Cancer Therapeutics

被引:62
作者
Fiaschetti, G. [2 ]
Grotzer, M. A. [2 ]
Shalaby, T. [2 ]
Castelletti, D. [2 ]
Arcaro, A. [1 ]
机构
[1] Univ Bern, Dept Clin Res, CH-3004 Bern, Switzerland
[2] Univ Childrens Hosp, Dept Oncol, Zurich, Switzerland
关键词
Anticancer therapeutics; quassinoids; Simaroubaceae; tumor; NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; INITIATION-FACTOR; 4E; C-MYC; TRANSLATION INITIATION; CELL-DIFFERENTIATION; SIGNALING PATHWAYS; ANTITUMOR AGENTS; BRUCEA-[!text type='JAVA']JAVA[!/text]NICA; THERAPY;
D O I
10.2174/092986711794839205
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Quassinoids are a group of compounds extracted from plants of the Simaroubaceae family, which have been used for many years in folk medicine. These molecules gained notoriety after the initial discovery of the anti-leukemic activity of one member, bruceantin, in 1975. Currently over 150 quassinoids have been isolated and classified based on their chemical structures and biological properties investigated in vitro and in vivo. Many molecules display a wide range of inhibitory effects, including anti-inflammatory, anti-viral, anti-malarial and anti-proliferative effects on various tumor cell types. Although often the exact mechanism of action of the single agents remains unclear, some agents have been shown to affect protein synthesis in general, or specifically HIF-1 alpha and MYC, membrane polarization and the apoptotic machinery. Considering that future research into chemical modifications is likely to generate more active and less toxic derivatives of natural quassinoids, this family represents a powerful source of promising small molecules targeting key pro-survival signaling pathways relevant for diverse pathologies. Here, we review available knowledge of functionality and possible applications of quassinoids and quassinoid derivatives, spanning traditional use to the potential impact on modern medicine as cancer therapeutics.
引用
收藏
页码:316 / 328
页数:13
相关论文
共 73 条
[1]  
Arseneau J C, 1983, Invest New Drugs, V1, P239
[2]   OPINION Is NF-κB a good target for cancer therapy? Hopes and pitfalls [J].
Baud, Veronique ;
Karin, Michael .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (01) :33-40
[3]   Quassinoid Inhibition of AP-1 Function Does Not Correlate with Cytotoxicity or Protein Synthesis Inhibition [J].
Beutler, John A. ;
Kang, Moon-Il ;
Robert, Francis ;
Clement, Jason A. ;
Pelletier, Jerry ;
Colburn, Nancy H. ;
McKee, Tawnya C. ;
Goncharova, Ekaterina ;
McMahon, James B. ;
Henrich, Curtis J. .
JOURNAL OF NATURAL PRODUCTS, 2009, 72 (03) :503-506
[4]   Natural Products as Chemical Probes [J].
Carlson, Erin E. .
ACS CHEMICAL BIOLOGY, 2010, 5 (07) :639-653
[5]  
CASTELLETTI D, 2010, MOL CANC THER
[6]  
CHAN KL, 1986, PLANTA MED, P105, DOI 10.1055/s-2007-969091
[7]  
Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120
[8]   Brusatol-induced HL-60 cell differentiation involves NF-κB activation [J].
Cuendet, M ;
Gills, JJ ;
Pezzuto, JM .
CANCER LETTERS, 2004, 206 (01) :43-50
[9]   Antitumor activity of bruceantin: An old drug with new promise [J].
Cuendet, M ;
Pezzuto, JM .
JOURNAL OF NATURAL PRODUCTS, 2004, 67 (02) :269-272
[10]   Multiple myeloma regression mediated by bruceantin [J].
Cuendet, M ;
Christov, K ;
Lantvit, DD ;
Deng, YF ;
Hedayat, S ;
Helson, L ;
McChesney, JD ;
Pezzuto, JM .
CLINICAL CANCER RESEARCH, 2004, 10 (03) :1170-1179